In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes

There are currently no effective molecular targeted therapies for hepatocellular carcinoma (HCC), the third leading cause of cancer-related death worldwide. Enhancer of zeste homolog 2 (EZH2), a histone H3 lysine 27 (H3K27)-specific methyltransferase, has been emerged as novel anticancer target. Our...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tsang-Pai, Hong, Yi-Han, Tung, Kwang-Yi, Yang, Pei-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751912/
https://www.ncbi.nlm.nih.gov/pubmed/26973856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751912/
https://www.ncbi.nlm.nih.gov/pubmed/26973856

Ejemplares similares